CenTRion Therapeutics was granted a GB patent for their CNS platform range of triazine molecules aimed at tackling the unmet need in Multiple Sclerosis, Epilepsy, Neuropathic pain and other CNS disorders The CenTRion Therapeutics approach is designed to take back the intellectual initiative in drug discovery, by building on the experience and ingenuity of its founders